[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio0eb1226a":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":77},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dcio0eb1226a","美股ERAS为什么暴涨？","\u002Fdoc\u002Fdcio0eb1226a","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp> \u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">美股投资网分析，\u003C\u002Fspan>Erasca, Inc. (NASDAQ: ERAS) \u003Cspan style=\"font-family: DengXian;\">最近的股价暴涨是由一系列密集的重大利好消息和业务突破共同推动的。在过去半年左右的时间里，其股价飙升了超过\u003C\u002Fspan> 500%\u003Cspan style=\"font-family: DengXian;\">。导致其近期暴涨的核心原因可以归结为以下几个关键维度：\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">1. \u003Cspan style=\"font-family: DengXian;\">核心管线\u003C\u002Fspan> ERAS-0015 \u003Cspan style=\"font-family: DengXian;\">临床数据表现惊艳\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">2026\u003Cspan style=\"font-family: DengXian;\">年\u003C\u002Fspan>1\u003Cspan style=\"font-family: DengXian;\">月中旬，\u003C\u002Fspan>Erasca \u003Cspan style=\"font-family: DengXian;\">公布了其针对\u003C\u002Fspan> RAS \u003Cspan style=\"font-family: DengXian;\">突变实体瘤的在研新药\u003C\u002Fspan> ERAS-0015\u003Cspan style=\"font-family: DengXian;\">（\u003C\u002Fspan>AURORAS-1 \u003Cspan style=\"font-family: DengXian;\">一期临床试验）的早期数据。结果显示，该药物在\u003C\u002Fspan>**\u003Cspan style=\"font-family: DengXian;\">极低的剂量下（每天\u003C\u002Fspan> 8mg\u003Cspan style=\"font-family: DengXian;\">）\u003C\u002Fspan>**\u003Cspan style=\"font-family: DengXian;\">就观察到了确认的肿瘤部分缓解（\u003C\u002Fspan>Partial Responses\u003Cspan style=\"font-family: DengXian;\">），并且表现出非常优异的安全性和耐受性，未发现剂量限制性毒性。相比于同赛道的竞争对手（例如\u003C\u002Fspan> Revolution Medicines \u003Cspan style=\"font-family: DengXian;\">的药物需要高得多的剂量，且伴随较高的皮疹等副作用），\u003C\u002Fspan>Erasca \u003Cspan style=\"font-family: DengXian;\">的数据展现出了“同类最佳\u003C\u002Fspan> (Best-in-Class)\u003Cspan style=\"font-family: DengXian;\">”的潜力，这一消息直接点燃了市场情绪。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">2. \u003Cspan style=\"font-family: DengXian;\">财报盈利超出预期（\u003C\u002Fspan>2026\u003Cspan style=\"font-family: DengXian;\">年\u003C\u002Fspan>3\u003Cspan style=\"font-family: DengXian;\">月最新利好）\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">就在最近的\u003C\u002Fspan> 2026\u003Cspan style=\"font-family: DengXian;\">年\u003C\u002Fspan>3\u003Cspan style=\"font-family: DengXian;\">月\u003C\u002Fspan>19\u003Cspan style=\"font-family: DengXian;\">日，\u003C\u002Fspan>Erasca \u003Cspan style=\"font-family: DengXian;\">公布了第四季度财报。其每股收益（\u003C\u002Fspan>EPS\u003Cspan style=\"font-family: DengXian;\">）击败了华尔街的共识预期。超预期的财务表现进一步提振了投资者信心，刺激其股价在当天单日大涨超过\u003C\u002Fspan> 10%\u003Cspan style=\"font-family: DengXian;\">。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">3. \u003Cspan style=\"font-family: DengXian;\">扩大全球市场版图与达成新合作\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">拿下大中华区权益：\u003C\u002Fspan>2026\u003Cspan style=\"font-family: DengXian;\">年\u003C\u002Fspan>3\u003Cspan style=\"font-family: DengXian;\">月，\u003C\u002Fspan>Erasca \u003Cspan style=\"font-family: DengXian;\">宣布扩大与原研方（广州璧辰医药\u003C\u002Fspan> Joyo Pharmatech\u003Cspan style=\"font-family: DengXian;\">）的授权协议，将中国大陆、香港和澳门纳入其版图，从而获得了\u003C\u002Fspan> ERAS-0015 \u003Cspan style=\"font-family: DengXian;\">的全球独家权益。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">临床联合用药合作：\u003C\u002Fspan>3\u003Cspan style=\"font-family: DengXian;\">月初，公司宣布与\u003C\u002Fspan> Tango Therapeutics \u003Cspan style=\"font-family: DengXian;\">达成临床合作，共同评估\u003C\u002Fspan> ERAS-0015 \u003Cspan style=\"font-family: DengXian;\">与其他疗法的联合用药潜力，拓宽了药物的未来应用场景。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">4. \u003Cspan style=\"font-family: DengXian;\">华尔街投行密集上调目标价\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">基于优异的临床进展和全球化市场布局，近期华尔街资本普遍看好其前景。包括\u003C\u002Fspan> H.C. Wainwright\u003Cspan style=\"font-family: DengXian;\">、\u003C\u002Fspan>Stifel\u003Cspan style=\"font-family: DengXian;\">、\u003C\u002Fspan>Guggenheim \u003Cspan style=\"font-family: DengXian;\">和\u003C\u002Fspan> Mizuho \u003Cspan style=\"font-family: DengXian;\">在内的多家投资银行纷纷给出“买入”评级，并将\u003C\u002Fspan> Erasca \u003Cspan style=\"font-family: DengXian;\">的目标价大幅上调至\u003C\u002Fspan> $19 \u003Cspan style=\"font-family: DengXian;\">到\u003C\u002Fspan> $20 \u003Cspan style=\"font-family: DengXian;\">的区间。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">5. \u003Cspan style=\"font-family: DengXian;\">成功融资，消除了资金担忧\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">在\u003C\u002Fspan>1\u003Cspan style=\"font-family: DengXian;\">月份发布利好数据后，\u003C\u002Fspan>Erasca \u003Cspan style=\"font-family: DengXian;\">趁热打铁，成功完成了\u003C\u002Fspan> 2.58 \u003Cspan style=\"font-family: DengXian;\">亿美元的超额增发融资。目前公司拥有约\u003C\u002Fspan> 4.34 \u003Cspan style=\"font-family: DengXian;\">亿美元的强劲现金流，官方预计足以支撑其运营和研发到\u003C\u002Fspan> 2028 \u003Cspan style=\"font-family: DengXian;\">年下半年，这彻底打消了生物科技公司常见的短期资金链断裂风险。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">综合来看，\u003C\u002Fspan>Erasca \u003Cspan style=\"font-family: DengXian;\">凭借在精准抗癌领域的硬核临床数据，叠加充沛的资金储备和不断扩大的商业版图，成功吸引了大量市场资金的追捧。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>","https:\u002F\u002Fwww.tradesmax.com\u002Fimages\u002Fa_Stock\u002FE\u002FERAS\u002FERAS.jpg","2026-03-21T00:22:08","2026.03.21","2026\u002F03\u002F21",49796,[22],"ERAS","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" target=\"_blank\" rel=\"noopener noreferrer\">\u003Cimg style=\"display:block;margin-left:auto;margin-right:auto;\" src=\"https:\u002F\u002Fstockwewebfiles.blob.core.windows.net\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":68,"summaryHtml":73,"aboutTitle":74,"aboutHtml":75,"copyrightHtml":76},[44,47,50,53,56,59,62,65],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fplan",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":60,"url":61},"美股课程","\u002Fcol\u002Fvideos",{"label":63,"url":64},"免责声明","\u002Fdisclaimer",{"label":66,"url":67},"联系我们","\u002FContactUs",[69,70,71,72],"https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 StockWe.com 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理千万级股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":78,"search":79,"searchPlaceholder":79,"hotContent":80,"draft":81,"noData":82,"searchNoData":83,"edit":84,"editVideo":85,"courseContent":86,"more":87,"buyNow":88,"subscribeNow":89,"encoding":90,"paidContent":91},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","编辑","编辑视频","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]